Charles River Laboratories CRL Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's deferred revenue?
- Charles River Laboratories (CRL) reported deferred revenue of $194.33M in Q1 2026.
- How has Charles River Laboratories's deferred revenue changed year-over-year?
- Charles River Laboratories's deferred revenue decreased by 22.4% year-over-year, from $250.46M to $194.33M.
- What is the long-term trend for Charles River Laboratories's deferred revenue?
- Over 5 years (2020 to 2025), Charles River Laboratories's deferred revenue has grown at a 0.2% compound annual growth rate (CAGR), from $207.94M to $210.42M.
- What does deferred revenue mean?
- Money received from customers for work not yet completed.
- How do you interpret deferred revenue?
- An increase signals strong future demand and sales growth, while a decrease may indicate a slowdown in new bookings or rapid fulfillment.
- How does deferred revenue compare across companies?
- High levels are common in contract research organizations (CROs) due to the nature of long-term service agreements.